SU1685454A1 - Burn treatment agent "xymedon" - Google Patents
Burn treatment agent "xymedon" Download PDFInfo
- Publication number
- SU1685454A1 SU1685454A1 SU772452993A SU2452993A SU1685454A1 SU 1685454 A1 SU1685454 A1 SU 1685454A1 SU 772452993 A SU772452993 A SU 772452993A SU 2452993 A SU2452993 A SU 2452993A SU 1685454 A1 SU1685454 A1 SU 1685454A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- xymedon
- dimethyldihydropyrimidone
- burn
- treatment agent
- agent
- Prior art date
Links
- JLKVZOMORMUTDG-UHFFFAOYSA-N 1-(2-hydroxyethyl)-4,6-dimethylpyrimidin-2-one Chemical compound CC=1C=C(C)N(CCO)C(=O)N=1 JLKVZOMORMUTDG-UHFFFAOYSA-N 0.000 title claims description 8
- XBCXJKGHPABGSD-UHFFFAOYSA-N methyluracil Natural products CN1C=CC(=O)NC1=O XBCXJKGHPABGSD-UHFFFAOYSA-N 0.000 claims description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000700198 Cavia Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- SZIFAVKTNFCBPC-UHFFFAOYSA-N 2-chloroethanol Chemical compound OCCCl SZIFAVKTNFCBPC-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
мm
ёyo
Изобретение относитс к медицине противоожоговых средств.This invention relates to anti-burn medicine.
Цель изобретени - повышение фармакологической активности.The purpose of the invention is to increase the pharmacological activity.
В качестве лекарственного средства примен ют N-( /9-оксиэтилу-4,6-диметилди- гидропиримидон-2 (Ксимедон), обладающий высокой регенеративной активностью, известный как химическое соединение.N- ((9-hydroxyethyl-4,6-dimethyldihydropyrimidone-2 (Xymedon)) with a high regenerative activity, known as a chemical compound, is used as a drug.
Ксимедон - N- /3-оксиэтил)-4,6-диме- тилдигидропиримидон-2 - получен взаимодействием гидрохлорида 2-ок- си-4,6-диметилпиримидина с этилен- хлоргидрином в присутствии 2 моль NaOH в среде н-бутанола.Xymedon - N- / 3-hydroxyethyl) -4,6-dimethyldihydropyrimidone-2 - is obtained by reacting 2-ox-4,6-dimethylpyrimidine hydrochloride with ethylene chlorohydrin in the presence of 2 mol of NaOH in n-butanol medium.
Препарат представл ет собой кристаллический порошок от белого до светло-розового цвета с т.пл 137 , 5-139,5°С Хорошо растворим в воде.The preparation is a white to light pink crystalline powder with mp 137, 5-139.5 ° C. It is soluble in water.
П р и м е р. В опыт берутс морские свинки самцы и самки массой 300-380 г, за день до нанесени ожога необходима поверхность депиллируетс 10%-ным раствором сернистого натри , нанос тс по 2 стандартных ожога на боковые поверхности туловища. На следующий день после ожога в зависимости от принадлежности к группам (опытна , контрольна группа, леченна метилурацилом) начинаетс введение ксимедона в дозе 750 мг/кг, метилурацила - в дозе 100 мг/кг и физиологического раствора по 0.5 мл на 100 г массы ежедневно 1 раз в сутки. Сроки наблюдени вз ты в динамике: 37, 15, 20, 25 и 30 сут. В опытной группе на 25-й день у всех исследуемых животных практически наступает выздоровление , в группе, леченной метилурацилом,PRI me R. Guinea pigs, males and females weighing 300–380 g, are taken into the experiment, the day before the burn is applied, the surface is depillated with a 10% solution of sodium sulphide, 2 standard burns are applied to the lateral surfaces of the body. The day after the burn, depending on the group membership (experimental, control group, treated with methyluracil), xymedon is administered at a dose of 750 mg / kg, methyluracil at a dose of 100 mg / kg and saline at 0.5 ml per 100 g of weight daily 1 once a day. The time of observation is taken in the dynamics: 37, 15, 20, 25 and 30 days. In the experimental group on the 25th day, all the studied animals almost recovered, in the group treated with methyluracil,
О 00 СЯO 00 SJ
ЈьЈ
слcl
JVJv
подобна картин.) заживлени отмечена лишь к 30-му дню.similar to the pictures.) of healing is noted only by the 30th day.
Морские свинки забивались путем дека- питации, при забое забирали кровь дл проведени исследовани р да биохимических показателей.Guinea pigs were slaughtered by decapitalization, blood was collected at slaughter for a series of biochemical indicators.
Использование ксимедона показало, что он вл етс эффективным средством лечени ожогов в силу своей высокой лротмвовоспалительной и регенеративной 10 и хронических лейкемических формах лей- активности. Лечебный эффект выражаетс в коза, лимфогрануломотоза, злокачествен- быстрейшем заживлении раневой поверхности , отпадении струпа на более ранних сроках, в улучшении морфологической и чи- стохимической картины поврежденной ко- 15 жи и восстановлении биохимических показателей, указывающих на нормализацию метаболических процессов.The use of xymedon has shown that it is an effective treatment for burns due to its high lung inflammatory and regenerative 10 and chronic leukemic forms of leukemia. The therapeutic effect is expressed in goat, lymphogranulomatosis, malignancy, faster healing of the wound surface, elimination of the scab in earlier periods, improvement of the morphological and computational picture of the damaged skin and restoration of biochemical indicators indicating normalization of metabolic processes.
ных заболевани х костного мозга.diseases of the bone marrow.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU772452993A SU1685454A1 (en) | 1977-02-14 | 1977-02-14 | Burn treatment agent "xymedon" |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU772452993A SU1685454A1 (en) | 1977-02-14 | 1977-02-14 | Burn treatment agent "xymedon" |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1685454A1 true SU1685454A1 (en) | 1991-10-23 |
Family
ID=20695736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU772452993A SU1685454A1 (en) | 1977-02-14 | 1977-02-14 | Burn treatment agent "xymedon" |
Country Status (1)
| Country | Link |
|---|---|
| SU (1) | SU1685454A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4323615A1 (en) * | 1993-07-12 | 1995-01-19 | Schreiner Edelgard | Compositions to prevent premature ageing of the skin |
| WO2008002196A1 (en) | 2006-06-19 | 2008-01-03 | Lev Davidovich Rasnetsov | Pharmaceutical composition for treating burns (variants) and a method for the production thereof (variants) |
-
1977
- 1977-02-14 SU SU772452993A patent/SU1685454A1/en active
Non-Patent Citations (1)
| Title |
|---|
| Резник B.C., Пашкуров Н.Г. Взаимодействие окси- и меркаптопиримидинов с этилен- и пропиленхлоргидринами. - Извести АН СССР, сер. Хими , 1966, № 91Б13. * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4323615A1 (en) * | 1993-07-12 | 1995-01-19 | Schreiner Edelgard | Compositions to prevent premature ageing of the skin |
| WO2008002196A1 (en) | 2006-06-19 | 2008-01-03 | Lev Davidovich Rasnetsov | Pharmaceutical composition for treating burns (variants) and a method for the production thereof (variants) |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4708965A (en) | Method of treating herpes virus infections with N,N'-diacetylcystine and derivatives | |
| Moncrief et al. | Use of topical antibacterial therapy in the treatment of the burn wound | |
| RU95106821A (en) | Cyclopeptides, method of their synthesis, pharmaceutical composition and method of its preparing | |
| JPS6470415A (en) | Skin permeable remedy system | |
| DE4394931T1 (en) | Use of norastemizole for the treatment of allergic diseases | |
| KR880009948A (en) | Novel naphthalene derivatives for use as antiallergic and anti-inflammatory agents | |
| MY113803A (en) | Fluorophenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as medicament or diagnostic, and medicament containing them. | |
| WO1991002529A2 (en) | Product and method for killing abnormal vertebrate cells | |
| FI854926A0 (en) | FREEZING FOR PHARMACOLOGICAL ACTIVE PYRROLOBENSIMIDAZOLER. | |
| ES472847A1 (en) | 2-Bromo-ergosine and its acid addition salts, method for its preparation and its application as a medicine. | |
| SU1685454A1 (en) | Burn treatment agent "xymedon" | |
| KR890006621A (en) | Anti-anxiety | |
| KR920700627A (en) | Novel use of 1-phenyl-2-aminoethanol derivatives as therapeutic agents | |
| NO173137C (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE COMPOUNDS | |
| EP0030023A3 (en) | A heterocyclic compound and its synthesis, pharmaceutical formulations thereof and the use of the compounds and the formulations in medicine | |
| Fox et al. | Virulence of Pseudomonas infection in burned rats and mice: comparative efficacy of silver sulfadiazine and mafenide | |
| PT653939E (en) | USE OF A HYMENOPTERE POISON FOR THE MANUFACTURE OF A DRUG FOR THE TREATMENT OF DNA VIRUS INFECTIONS | |
| SU1832496A1 (en) | Antiseptic agent "miramistin" for venereal disease prophylaxis | |
| SE8203856D0 (en) | NOVEL DERIVATIVES OF GUANINE II | |
| DE3275060D1 (en) | Use of beta-(1-adamantyl)-alpha, alpha-dimethylethylamine for the manufacture of a medicament for the treatment of otitis externa in dogs | |
| Brodsky et al. | Effect of testosterone enanthate and alkylating agents on multiple myeloma | |
| ES479805A1 (en) | Antibacterial monic acid C derivatives, processes for their preparation and compositions containing them. | |
| ATE22009T1 (en) | USE OF ALPHA, ALPHADIALKYLADAMANTYLETHYLAMINES IN THE TREATMENT OF MEASLES VIRUS. | |
| WILSON | Sulfanilamide in Treatment of Acute Lupus Erythematosus: Failure with Well Controlled Administration | |
| ES438537A1 (en) | 1-(2,4,6-Trihydroxyphenyl)-propanedione-(1,2)-compounds and therapeutic compositions |